Cargando…
Fexapotide Triflutate Induces Selective Prostate Glandular Pharmaco-Ablation in the Rat
INTRODUCTION: A clinical challenge for interventional prostate treatments for localized prostate cancer has been to elicit cancer tissue eradication which can avoid undesirable toxicities and irreparable damage to adjacent structures. Fexapotide triflutate (FT) has been shown in human clinical trial...
Autores principales: | Averback, Paul, Gohal, Rajna, Fuska, Marta, Prins, Kathleen, Wang, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929934/ https://www.ncbi.nlm.nih.gov/pubmed/31909043 http://dx.doi.org/10.2147/RRU.S231334 |
Ejemplares similares
-
Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results
por: Shore, Neal, et al.
Publicado: (2020) -
Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement
por: Shore, Neal, et al.
Publicado: (2018) -
Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Shore, Neal, et al.
Publicado: (2019) -
Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis
por: Wei, Yifan, et al.
Publicado: (2022) -
Pharmaco-prosthodontics revisited
por: Jagadeeshwaran, A. R., et al.
Publicado: (2012)